Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 4Recruiting 3Completed 3Not yet recruiting 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Virus Diseases 1Urinary Bladder Neoplasms 1Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma in Situ 1Adenoviridae Infections 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Oncolytic Virotherapy × Clear all
NCT01438112 2021-04-14

BOND

CG Oncology, Inc.

Phase 2/3 Terminated
22 enrolled
Genitourinary

Adenoviridae Infections, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Virus Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡